港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

映恩生物-B

215.600

+8.2003.95%

成交量：21.58萬

成交額：4,641.99萬

市值：184.20億

市盈率：-1.53

高：219.600

開：207.400

低：202.400

收：207.400

資料載入中...

總覽公司新聞公告

【新股IPO】映恩生物(09606)首掛開報181港元較招股價高91.33% 一手可賺8640港元

【映恩生物高開超90% 昨日暗盤迎來大漲】截至發稿，映恩生物(09606.HK)漲91.33%。消息方面，該公司在昨日的暗盤大漲87.1%。根據公開資料，映恩生物是一家專注於新一代抗體偶聯藥物研發的創新生物製藥企業，致力於爲癌症和自身免疫性疾病等患者研發新一代ADC創新藥物。

映恩生物(09606.HK)上市首日高開91.33%，報181港元。

新股首日 | 映恩生物-B(09606)首掛上市早盤高開91.33% 公司為ADC創新藥物研發商

港股開盤｜恒指高開0.87%，科指高開0.85%！映恩生物-B首掛大幅高開逾91%

老虎资讯综合

【新股IPO】映恩生物(09606)定價94.6港元一手中籤率80.01%

映恩生物-B：最終發售價為每股94.6港元香港公開發售獲115.14倍認購

【港股IPO動態：今日映恩生物上市】今日映恩生物(9606.HK)上市，無新股申購。

映恩生物赴港上市，港股18A行業迎來第二春？

老虎暗盤 | 映恩生物收漲82.88%，一手賺7840港元

老虎资讯综合

新股暗盤 | 映恩生物-B(09606)暗盤收漲82.88% 每手賺7840港元

智通财经网

新股暗盤 | 映恩生物-B(09606)暗盤盤初上漲64.59% 每手賺6110港元

火爆！18A最大IPO誕生！映恩生物創ADC港股神話

映恩生物(09606)港股IPO創18A生物科技多項紀錄全球資本熱捧ADC賽道領軍者

智通财经网

映恩生物IPO，一場資本對賭下的造夢遊戲

Ofweek光电信息网

認購火爆，映恩生物打響18A IPO重啓信號槍

無懼市場波動！映恩生物趕赴港股IPO，2022年以來18A募資王來了

新股孖展統計 | 4月9日

新股孖展統計 | 4月8日

新股孖展統計 | 4月7日

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/09606/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09606","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09606\",,,,,undefined,":{"symbol":"09606","market":"HK","secType":"STK","nameCN":"映恩生物-B","latestPrice":215.6,"timestamp":1746173305036,"preClose":207.4,"halted":0,"volume":215800,"delay":0,"floatShares":85436500,"shares":85436464,"eps":-140.83735726203204,"marketStatus":"已收盤","change":8.2,"latestTime":"05-02 16:08:25","open":207.4,"high":219.6,"low":202.4,"amount":46419870,"amplitude":0.082932,"askPrice":215.8,"askSize":100,"bidPrice":215.6,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-140.83736798806476,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1746495000000},"marketStatusCode":5,"adr":0,"listingDate":1744646400000,"exchange":"SEHK","adjPreClose":207.4,"openAndCloseTimeList":[[1746149400000,1746158400000],[1746162000000,1746172800000]],"volumeRatio":0.401806,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09606\",,,,,undefined,":{"symbol":"09606","floatShares":85436500,"roa":"-6.51%","roe":"--","lyrEps":-140.837368,"volumeRatio":0.401806,"shares":85436464,"dividePrice":0,"high":219.6,"amplitude":0.082932,"preClose":207.4,"low":202.4,"week52Low":178.8,"pbRate":"-8.47","psRate":"8.85","week52High":234.6,"institutionHeld":0,"latestPrice":215.6,"committee":0.333333,"eps":-140.83735726203204,"divideRate":0,"volume":215800,"delay":0,"ttmEps":-140.83736798806476,"open":207.4,"prevYearClose":94.6,"prevWeekClose":207.4,"prevMonthClose":207.4,"prevQuarterClose":94.6,"fiveDayClose":225,"twentyDayClose":94.6,"sixtyDayClose":94.6},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09606\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2527989106","title":"【新股IPO】映恩生物(09606)首掛開報181港元 較招股價高91.33% 一手可賺8640港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527989106","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527989106?lang=zh_tw&edition=fundamental","pubTime":"2025-04-15 09:30","pubTimestamp":1744680613,"startTime":"0","endTime":"0","summary":"金吾财讯 | 映恩生物(09606)首挂开报181港元，较招股价高91.33%，盘前成交473.63万股，成交额7.82亿港元，不计手续费，每手100股，账面赚8640港元。据招股结果显示，股份每股定价94.6港元，集资16.4亿港元，净额约15.13亿港元，一手中签率80.01%，认购10手可稳获一手。股份于公开发售部分接获26857份有效申请，认购额115.14倍；国际发售部分认购额13.52倍。","market":"fut","thumbnail":"https://static.szfiu.com/news/20220324/YjI0MWRiZGM3ZjA2MTU3MTE2NDgwOTA4MzEyNTY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20220324/YjI0MWRiZGM3ZjA2MTU3MTE2NDgwOTA4MzEyNTY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1957188","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"gpt_icon":0},{"id":"2527628177","title":"【映恩生物高開超90% 昨日暗盤迎來大漲】截至發稿，映恩生物(09606.HK)漲91.33%。消息方面，該公司在昨日的暗盤大漲87.1%。根據公開資料，映恩生物是一家專注於新一代抗體偶聯藥物研發的創新生物製藥企業，致力於爲癌症和自身免疫性疾病等患者研發新一代ADC創新藥物。","url":"https://stock-news.laohu8.com/highlight/detail?id=2527628177","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527628177?lang=zh_tw&edition=fundamental","pubTime":"2025-04-15 09:27","pubTimestamp":1744680474,"startTime":"0","endTime":"0","summary":"截至发稿，映恩生物(09606.HK)涨91.33%。消息方面，该公司在昨日的暗盘大涨87.1%。根据公开资料，映恩生物是一家专注于新一代抗体偶联药物研发的创新生物制药企业，致力于为癌症和自身免疫性疾病等患者研发新一代ADC创新药物。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5297752f2e4ee415e69380642a004984","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/15092749540314.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["09606","159992","ADC","BK4080","BK1161","BK4231","06978","BK1574"],"gpt_icon":0},{"id":"2527172231","title":"映恩生物(09606.HK)上市首日高開91.33%，報181港元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2527172231","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527172231?lang=zh_tw&edition=fundamental","pubTime":"2025-04-15 09:22","pubTimestamp":1744680162,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5297752f2e4ee415e69380642a004984","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["09606"],"gpt_icon":0},{"id":"2527177835","title":"新股首日 | 映恩生物-B(09606)首掛上市 早盤高開91.33% 公司為ADC創新藥物研發商","url":"https://stock-news.laohu8.com/highlight/detail?id=2527177835","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527177835?lang=zh_tw&edition=fundamental","pubTime":"2025-04-15 09:21","pubTimestamp":1744680097,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，映恩生物-B首挂上市，公告显示，每股定价94.6港元，共发行1733.23万股股份，每手100股，所得款项净额约15.13亿港元。截至发稿，涨91.33%，报181港元，成交额7.82亿港元。公开资料显示，映恩生物于2020年正式运营，是抗体偶联药物领域的全球领跑者。其中多项临床阶段的ADC，在17个国家230多个临床试验中心开展7项全球临床试验，已入组超过2000多名患者，50%患者来自海外。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5297752f2e4ee415e69380642a004984","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1278631.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4080","BK1574","ADC","159992","06978","BK4231","09606","BK1161"],"gpt_icon":1},{"id":"1166058336","title":"港股開盤｜恒指高開0.87%，科指高開0.85%！映恩生物-B首掛大幅高開逾91%","url":"https://stock-news.laohu8.com/highlight/detail?id=1166058336","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166058336?lang=zh_tw&edition=fundamental","pubTime":"2025-04-15 09:20","pubTimestamp":1744680030,"startTime":"0","endTime":"0","summary":"4月15日，港股开盘，恒指开涨0.87%，科指开涨0.85%。科网股普涨，阿里巴巴涨超3%，腾讯、快手涨超2%；黄金股普涨，赤峰黄金涨超2%，续刷历史新高；映恩生物-B首挂大幅高开逾91%，此前获115.14倍认购，一手中签率80.01%。","market":"hk","thumbnail":"https://static.tigerbbs.com/c1cb237e736a4e03c939622e7b71e8e7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/c1cb237e736a4e03c939622e7b71e8e7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5297752f2e4ee415e69380642a004984","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HHImain","BK4614","HSImain","09606","HSCEI","YANG","513600","07226","HSTECH","MHImain","02833","MCHmain","HSI"],"gpt_icon":0},{"id":"2527106663","title":"【新股IPO】映恩生物(09606)定價94.6港元 一手中籤率80.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2527106663","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527106663?lang=zh_tw&edition=fundamental","pubTime":"2025-04-15 08:37","pubTimestamp":1744677451,"startTime":"0","endTime":"0","summary":"金吾财讯 | 映恩生物(09606)公布招股结果，每股定价94.6港元，集资16.4亿港元，净额约15.13亿港元，每手100股，一手中签率80.01%，认购10手可稳获一手。股份于公开发售部分接获26857份有效申请，认购额115.14倍；国际发售部分认购额13.52倍。","market":"sh","thumbnail":"https://static.szfiu.com/news/20220324/MzRhMTE1MTUwMjgzODI3Nw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20220324/MzRhMTE1MTUwMjgzODI3Nw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1957181","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"gpt_icon":0},{"id":"2527752127","title":"映恩生物-B：最終發售價為每股94.6港元 香港公開發售獲115.14倍認購","url":"https://stock-news.laohu8.com/highlight/detail?id=2527752127","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527752127?lang=zh_tw&edition=fundamental","pubTime":"2025-04-15 07:31","pubTimestamp":1744673460,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　映恩生物-B（09606）公布配发结果，香港公开发售的发售股份数目（经重新分配后调整）为753.58万股，国际发售的发售股份数目（经计及发售量调整权获悉数行使及经重新分配后调整）为979.65万股。最终发售价为每股94.6港元，全球发售净筹约15.13亿港元。每手100股，预期股份将于2025年4月15日（星期二）开始在联交所买卖。\n　　其中，香港公开发售获115.14倍认购，国际配售获13.52倍认购。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggipo/2025-04-15/doc-inetevzx7616315.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09606"],"gpt_icon":0},{"id":"2527123797","title":"【港股IPO動態：今日映恩生物上市】今日映恩生物(9606.HK)上市，無新股申購。","url":"https://stock-news.laohu8.com/highlight/detail?id=2527123797","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527123797?lang=zh_tw&edition=fundamental","pubTime":"2025-04-15 06:11","pubTimestamp":1744668671,"startTime":"0","endTime":"0","summary":"今日映恩生物(9606.HK)上市，无新股申购。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/15061149537162.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["HSTECH","YANG","09606","BK4614"],"gpt_icon":0},{"id":"2527166792","title":"映恩生物赴港上市，港股18A行業迎來第二春？","url":"https://stock-news.laohu8.com/highlight/detail?id=2527166792","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527166792?lang=zh_tw&edition=fundamental","pubTime":"2025-04-14 20:57","pubTimestamp":1744635479,"startTime":"0","endTime":"0","summary":"映恩生物-B（09606.HK）将于4月15日在港交所正式挂牌上市。市场颇为关注的是，该公司国际配售倍数超过14倍，募资金额超过2亿美元。同时，公司此次上市还吸引了包括BioNTech、富国基金、易方达等在内的15家国际长线资本及头部公募作为基石投资者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202504143376333317.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504143376333317.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["YANG","HSTECH","09606","BK4614"],"gpt_icon":1},{"id":"1127712483","title":"老虎暗盤 | 映恩生物收漲82.88%，一手賺7840港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1127712483","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127712483?lang=zh_tw&edition=fundamental","pubTime":"2025-04-14 18:46","pubTimestamp":1744627569,"startTime":"0","endTime":"0","summary":"本周一（4月14日）， $映恩生物(09606)$ 老虎暗盘交易开启，截至收盘涨82.88%，一手赚7840港元。","market":"hk","thumbnail":"https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"老虎暗盘 | 映恩生物收涨82.88%，一手赚7840港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"gpt_icon":1},{"id":"2527813067","title":"新股暗盤 | 映恩生物-B(09606)暗盤收漲82.88% 每手賺7840港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527813067","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527813067?lang=zh_tw&edition=fundamental","pubTime":"2025-04-14 18:38","pubTimestamp":1744627106,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，映恩生物-B(09606)将于4月15日(周二)在香港挂牌。截至收盘，暗盘交易显示报价173.00港元，较招股价94.6港元上涨82.88%，每手100股，不计手续费，每手赚7840港元。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1278254.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["09606"],"gpt_icon":0},{"id":"2527907783","title":"新股暗盤 | 映恩生物-B(09606)暗盤盤初上漲64.59% 每手賺6110港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527907783","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527907783?lang=zh_tw&edition=fundamental","pubTime":"2025-04-14 16:32","pubTimestamp":1744619525,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，映恩生物-B(09606)将于4月15日(周二)在香港挂牌。截至发稿，暗盘交易显示报价155.70港元，较招股价94.6港元上涨64.59%，每手100股，不计手续费，每手赚6110港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1278114.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09606"],"gpt_icon":0},{"id":"2527984976","title":"火爆！18A最大IPO誕生！映恩生物創ADC港股神話","url":"https://stock-news.laohu8.com/highlight/detail?id=2527984976","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527984976?lang=zh_tw&edition=fundamental","pubTime":"2025-04-14 12:21","pubTimestamp":1744604460,"startTime":"0","endTime":"0","summary":"创近4年最大18A上市案例。同时，2025年医疗板块估值修复，港股18A企业平均股价涨幅翻倍，资本对ADC赛道的押注从谨慎转向狂热。ADC赛道进入价值重估阶段尽管IPO表现亮眼，映恩生物仍面临商业化与资金链考验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-04-14/doc-inetccsy8932121.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["YANG","BK4080","HSTECH","BK4614","ADC","09606","BK4231"],"gpt_icon":1},{"id":"2526672268","title":"映恩生物(09606)港股IPO創18A生物科技多項紀錄 全球資本熱捧ADC賽道領軍者","url":"https://stock-news.laohu8.com/highlight/detail?id=2526672268","media":"智通财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526672268?lang=zh_tw&edition=fundamental","pubTime":"2025-04-12 14:32","pubTimestamp":1744439520,"startTime":"0","endTime":"0","summary":"市场消息称，映恩生物此次IPO创下18A生物科技公司多项历史纪录：1、估值跃升三倍，公司成为港股18A板块中估值增幅最大的项目。映恩生物于2020年正式运营，是抗体偶联药物领域的全球领跑者。其中多项临床阶段的ADC，在17个国家230多个临床试验中心开展7项全球临床试验，已入组超过2000多名患者，50%患者来自海外。财务方面，得益于ADC出海，映恩生物营收增长态势无虞。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-04-12/doc-ineswvux1593953.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4080","HSTECH","BK4614","159837","ADC","YANG","BK4231","09606"],"gpt_icon":1},{"id":"2526618614","title":"映恩生物IPO，一場資本對賭下的造夢遊戲","url":"https://stock-news.laohu8.com/highlight/detail?id=2526618614","media":"Ofweek光电信息网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526618614?lang=zh_tw&edition=fundamental","pubTime":"2025-04-11 17:32","pubTimestamp":1744363920,"startTime":"0","endTime":"0","summary":"4月15日，映恩生物更进一步登陆港股市场，实现“上市梦”。然而光环之下，映恩生物的IPO更像是一场不容有失的资本突围战。显然，映恩生物已负担不起任何股票赎回要求，而IPO成功则是唯一的出路。相比之下，海内外药企对映恩生物ADC资产的疯抢更能说明问题。按照映恩生物的说法，这一平台肿瘤靶向性药物释放更精准、疗效更好、治疗窗口更宽。映恩生物几乎快把第一三共的临床开发团队打包挖回国内。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041117530394d2c705&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041117530394d2c705&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09606"],"gpt_icon":1},{"id":"2526637666","title":"認購火爆，映恩生物打響18A IPO重啓信號槍","url":"https://stock-news.laohu8.com/highlight/detail?id=2526637666","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526637666?lang=zh_tw&edition=fundamental","pubTime":"2025-04-11 17:06","pubTimestamp":1744362407,"startTime":"0","endTime":"0","summary":"18A久违的IPO火爆现象，重现江湖。4月10日，ADC明星药企映恩生物完成招股。据氨基君了解，结果堪称火爆，映恩生物完成超募，最终募资额超过2亿美元。这也意味着，映恩生物创造了2022年以来18A章节港股上市的多个“第一”：。这意味着，映恩生物刷新2022年以来18A融资额新纪录，而且远超均值。认购倍数，佐证了市场对于映恩生物的认可。另外还有两个维度，可以看到映恩生物IPO的备受瞩目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/255063","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["09606"],"gpt_icon":0},{"id":"2526339326","title":"無懼市場波動！映恩生物趕赴港股IPO，2022年以來18A募資王來了","url":"https://stock-news.laohu8.com/highlight/detail?id=2526339326","media":"财华社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526339326?lang=zh_tw&edition=fundamental","pubTime":"2025-04-11 14:02","pubTimestamp":1744351364,"startTime":"0","endTime":"0","summary":"作为一类新兴的大分子靶向药物，抗体偶联药物（ADC）结合了抗体的靶向能力和细胞毒性药物的杀伤效应，在肿瘤治疗领域展现出了优秀的疗效和潜力，有着“魔法子弹”的称号。","market":"hk","thumbnail":"https://images.finet.hk/photoLib/title/202504_1/979fee5c-c6f0-4d29-b133-7a55aedd9e7d.png","type":0,"news_type":0,"thumbnails":["https://images.finet.hk/photoLib/title/202504_1/979fee5c-c6f0-4d29-b133-7a55aedd9e7d.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/67f8b084230829fa60e23be1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"finet_stock","symbols":["BK4614","YANG","09606","HSTECH"],"gpt_icon":1},{"id":"2526135526","title":"新股孖展統計 | 4月9日","url":"https://stock-news.laohu8.com/highlight/detail?id=2526135526","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526135526?lang=zh_tw&edition=fundamental","pubTime":"2025-04-09 18:05","pubTimestamp":1744193110,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，映恩生物(09606)正在招股中。截止4月9日，富途、耀才、辉立等券商合计为映恩生物借出21.4606亿港元，超购逾12.7倍。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1276160.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09606"],"gpt_icon":0},{"id":"2525374898","title":"新股孖展統計 | 4月8日","url":"https://stock-news.laohu8.com/highlight/detail?id=2525374898","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525374898?lang=zh_tw&edition=fundamental","pubTime":"2025-04-08 18:46","pubTimestamp":1744109165,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，正力新能(03677)和映恩生物(09606)正在招股中。截止4月8日，富途、耀才、辉立等券商合计为正力新能借出1.3788亿港元，超购逾0.37倍；为映恩生物借出8.9954亿港元，超购逾4.7倍。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1275517.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09606","03677"],"gpt_icon":0},{"id":"2525092927","title":"新股孖展統計 | 4月7日","url":"https://stock-news.laohu8.com/highlight/detail?id=2525092927","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525092927?lang=zh_tw&edition=fundamental","pubTime":"2025-04-07 17:27","pubTimestamp":1744018057,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，正力新能(03677)和映恩生物(09606)正在招股中。截止4月7日，富途、耀才、辉立等券商合计为正力新能借出1.1142亿港元，超购逾0.1倍;为映恩生物借出4.2952亿港元，超购逾1.7倍。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1274677.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03677","09606"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":67,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09606\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09606\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09606\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09606\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09606","date":"2025-04-30","current":-15.806523,"percent":0.6,"low":-17.183112,"twenty":-16.756996,"median":-15.846935,"eighty":-14.905978,"high":-7.368305,"avg":-15.17124,"sd":2.625448,"marketCap":17719522633},"quantilePoints":[{"date":"2025-04-17","current":-14.905978,"twenty":-15.065639,"median":-14.442293,"eighty":-11.334487,"marketCap":16635152800},{"date":"2025-04-25","current":-15.846935,"twenty":-16.770434,"median":-15.576033,"eighty":-14.349556,"marketCap":17719522633},{"date":"2025-04-30","current":-15.806523,"twenty":-16.756996,"median":-15.846935,"eighty":-14.905978,"marketCap":17719522633}],"updateTime":1746201444902}}}